Owned by the Association for International Promotion & Study in Tumors (APSIT)
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Lung cancer is a malignant carcinoma which has the highest morbidity and mortality in Chinese population. Gefitinib, a tyrosine kinase (TK) inhibitor of epidermal growth factor receptor (EGFR), displays anti-t...